CO6180432A2 - Anticuerpos agonistas del trkb y usos de los mismos - Google Patents

Anticuerpos agonistas del trkb y usos de los mismos

Info

Publication number
CO6180432A2
CO6180432A2 CO09047482A CO09047482A CO6180432A2 CO 6180432 A2 CO6180432 A2 CO 6180432A2 CO 09047482 A CO09047482 A CO 09047482A CO 09047482 A CO09047482 A CO 09047482A CO 6180432 A2 CO6180432 A2 CO 6180432A2
Authority
CO
Colombia
Prior art keywords
antibody
seq
variable region
chain variable
trkb
Prior art date
Application number
CO09047482A
Other languages
English (en)
Spanish (es)
Inventor
Yan Wang
Steven B Cohen
Mar Nassoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CO6180432A2 publication Critical patent/CO6180432A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO09047482A 2006-11-09 2009-05-11 Anticuerpos agonistas del trkb y usos de los mismos CO6180432A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85816906P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
CO6180432A2 true CO6180432A2 (es) 2010-07-19

Family

ID=39365312

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09047482A CO6180432A2 (es) 2006-11-09 2009-05-11 Anticuerpos agonistas del trkb y usos de los mismos

Country Status (27)

Country Link
US (1) US20100150914A1 (fr)
EP (1) EP2087007A2 (fr)
JP (1) JP2010509354A (fr)
KR (1) KR20090088896A (fr)
CN (1) CN101573381A (fr)
AR (1) AR063640A1 (fr)
AU (1) AU2007316418A1 (fr)
BR (1) BRPI0719000A2 (fr)
CA (1) CA2669205A1 (fr)
CL (1) CL2007003236A1 (fr)
CO (1) CO6180432A2 (fr)
CR (1) CR10779A (fr)
DO (1) DOP2009000102A (fr)
EA (1) EA200970469A1 (fr)
EC (1) ECSP099392A (fr)
IL (1) IL198468A0 (fr)
MA (1) MA30922B1 (fr)
MX (1) MX2009004881A (fr)
NI (1) NI200900081U (fr)
NO (1) NO20092217L (fr)
PE (1) PE20081168A1 (fr)
RU (1) RU2009121641A (fr)
SM (1) SMAP200900040A (fr)
TN (1) TN2009000181A1 (fr)
TW (1) TW200829270A (fr)
WO (1) WO2008058127A2 (fr)
ZA (1) ZA200902943B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100089851A (ko) * 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
JP5420568B2 (ja) * 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
EP2408455B1 (fr) * 2009-03-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la cathepsine pour la prévention ou le traitement de troubles liés à l'obésité
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2013083826A2 (fr) * 2011-12-09 2013-06-13 Novo Nordisk A/S Agonistes du glp-1
CN102901815B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
WO2015173756A2 (fr) 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
EP3328898B8 (fr) * 2015-07-28 2024-04-10 6452728 Canada Corp. Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
TW201730206A (zh) * 2015-11-17 2017-09-01 葛蘭素史克智慧財產發展有限公司 用於治療神經及其他疾病之結合激動劑
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
WO2018195008A1 (fr) * 2017-04-21 2018-10-25 Mellitus, Llc Procédés et anticorps pour des applications liées au diabète
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
KR102986081B1 (ko) 2017-11-30 2026-07-06 리제너론 파아마슈티컬스, 인크. 항-trkb 모노클로날 항체 및 이의 사용 방법
WO2019165421A1 (fr) * 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Procédés de diagnostic utilisant des anticorps anti-muc1*
CN110818797B (zh) * 2018-08-09 2022-11-04 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
WO2023125485A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trkb et son application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5601820A (en) * 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
MX2007015292A (es) * 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Also Published As

Publication number Publication date
WO2008058127A9 (fr) 2008-08-21
MA30922B1 (fr) 2009-11-02
DOP2009000102A (es) 2010-10-31
CN101573381A (zh) 2009-11-04
RU2009121641A (ru) 2010-12-20
CA2669205A1 (fr) 2008-05-15
JP2010509354A (ja) 2010-03-25
TN2009000181A1 (en) 2010-10-18
SMAP200900040A (it) 2010-01-19
ECSP099392A (es) 2009-07-31
PE20081168A1 (es) 2008-09-22
EA200970469A1 (ru) 2010-04-30
TW200829270A (en) 2008-07-16
AU2007316418A1 (en) 2008-05-15
MX2009004881A (es) 2009-05-21
WO2008058127A3 (fr) 2008-10-02
US20100150914A1 (en) 2010-06-17
WO2008058127A2 (fr) 2008-05-15
NI200900081U (es) 2010-03-16
EP2087007A2 (fr) 2009-08-12
CL2007003236A1 (es) 2008-06-13
BRPI0719000A2 (pt) 2013-12-10
KR20090088896A (ko) 2009-08-20
AR063640A1 (es) 2009-02-04
ZA200902943B (en) 2010-05-26
NO20092217L (no) 2009-06-09
IL198468A0 (en) 2011-08-01
CR10779A (es) 2009-07-03

Similar Documents

Publication Publication Date Title
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
PE20120414A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
CR20140239A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (divisional de 2013-0351)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
PE20212198A1 (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
MX373426B (es) Moleculas de enlace a il-18.
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
EA200800812A1 (ru) Композиции антитела против cd3
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
PE20091520A1 (es) Anticuerpos bivalentes biespecificos
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
RU2011140509A (ru) Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
CL2009000090A1 (es) Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
CO6150192A2 (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos
AR065496A1 (es) Anticuerpos anti- il-23 r
AR073140A1 (es) Anticuerpos anti-il-23r disenados

Legal Events

Date Code Title Description
FA Application withdrawn